5 August 2016 - The public submission process is now closed. ...
20 July 2016 - CADTH has recommended that alirocumab (Praluent) be reimbursed in Canada. ...
8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...
6 January 2016 - The PBAC noted that the intent of the submission was to initiate a dialogue rather than ...
24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...
15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...
15 December 2015 - The dossier did not contain appropriate data for patients with hypercholesterolaemia nor for mixed dyslipidaemia. ...